ADAM9 drives PD-L1 shedding via IL-6 suppression and exploring therapeutic role of Bufalin treatment in hepatocellular carcinoma
{{output}}
The treatment landscape for advanced hepatocellular carcinoma (HCC) has changed significantly with the recent introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as those for programmed cell death ligand 1 (PD-L1). However, th... ...
